Literature DB >> 22525448

Myasthenia gravis in Jamaican children: a 12-year institutional review.

R Melbourne Chambers1, S Forrester, R Gray, J Tapper, H Trotman.   

Abstract

BACKGROUND: Myasthenia gravis is uncommon in children. The clinical characteristics in children of the English-speaking Caribbean have not been documented previously.
OBJECTIVE: To describe the clinical characteristics and outcome of children with myasthenia gravis at two tertiary hospitals in Jamaica.
METHODS: The case-notes of all children with a diagnosis of myasthenia gravis managed at the University Hospital of the West Indies and Bustamante Hospital for Children between January 1994 and December 2005 were reviewed.
RESULTS: There were 34 children; mean age of onset of illness was 7.5 years and mean period of follow-up was 38.5 months. The male-to-female ratio was 1:1.3. Nineteen (59%) presented with ocular manifestations; 47% of these developed signs of generalised involvement. Most were treated with pyridostigmine and prednisone. Eight patients had thymectomy. Four patients (12%) entered remission. There were two deaths.
CONCLUSIONS: Myasthenia gravis in Jamaican children is similar to that in other populations. It is more common in female children. Most children present with ocular manifestations and remission occurs infrequently.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22525448     DOI: 10.1179/1465328111Y.0000000042

Source DB:  PubMed          Journal:  Paediatr Int Child Health        ISSN: 2046-9047            Impact factor:   1.990


  2 in total

1.  Long-term outcome of 424 childhood-onset myasthenia gravis patients.

Authors:  Mengcui Gui; Xuan Luo; Jing Lin; Yue Li; Min Zhang; Xiaofan Zhang; Mingshan Yang; Wei Wang; Bitao Bu
Journal:  J Neurol       Date:  2015-01-15       Impact factor: 4.849

2.  Clinical characteristics and outcome predictors of a Chinese childhood-onset myasthenia gravis cohort.

Authors:  Lifen Yang; Yulin Tang; Fang He; Ciliu Zhang; Miriam Kessi; Jing Peng; Fei Yin
Journal:  Front Pediatr       Date:  2022-09-29       Impact factor: 3.569

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.